Skip to content

Inspection Record

Bello Bio LLC — FDA 483 Findings

US FDAInspected 2025-12-16Published 2026-10-27 16 findingsMaterial and supplier controlOther quality systemLabeling and packagingAseptic processing and sterility assuranceComplaint and recall handlingQuality unit oversightDocumentation and recordsStability and storageEquipment and facilityProcess validationLaboratory and QC controls

Inspectors Garrad R Poole · Emily S Mcgann · Laurissa S FlowersThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Material and supplier control

There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

2Other quality system

The eligibility of an HCT/P donor was not documented by a responsible person, based on results of donor screening and donor testing.

3Labeling and packaging

Procedures designed to assure that correct labels and labeling are used for drug products are not written.

4Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include validation of the aseptic process.

5Complaint and recall handling

Procedures describing the handling of all written and oral complaints regarding a drug product are not established.

6Quality unit oversight

There is no quality control unit.

7Documentation and records

Batch production and control records do not include complete information relating to the production and control of each batch.

8Other quality system

After the completion of the donor-eligibility determination, HCT/Ps were not accompanied with a statement whether the donor has been determined to be eligible or ineligible, based on the results of screening and testing.

9Material and supplier control

Written procedures are lacking which describe in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval and rejection of components and drug product containers.

10Stability and storage

There is no written testing program designed to assess the stability characteristics of drug products.

11Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

12Equipment and facility

Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

13Quality unit oversight

Drug products are not quarantined before being released by the quality control unit.

14Other quality system

Procedures were not designed to ensure compliance with the donor eligibility requirements.

15Process validation

Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

16Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that components conform to appropriate standards of identity, strength, quality and purity.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-27. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Bello Bio LLC company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.